Schedule B investigator-identified and sponsor-assessed DLTs
Patient’s starting dose cohort . | Dose when DLT occurred . | AE recorded as DLT . | Was the AE serious? . | Severity . | Relationship to MRZ/Dex . | Action taken with MRZ /Dex . | Outcome . |
---|---|---|---|---|---|---|---|
RP2D 0.5 mg/m2 | 0.5 mg/m2 | Nausea | Yes | Grade 3 | MRZ probable/Dex not related | None | Resolved |
RP2D 0.5 mg/m2 | 0.5 mg/m2 | Confusional state | Yes | Grade 4 | MRZ probable/Dex not related | MRZ discontinued | Resolved |
0.6 mg/m2 | 0.4 mg/m2 | Gait disturbance | No | Grade 2 | MRZ probable/Dex not related | MRZ dose reduced, dose delayed | Resolved |
0.6 mg/m2 | 0.6 mg/m2 | Paranoia | No | Grade 2 | MRZ possible/Dex not related | MRZ discontinued | Resolved |
Patient’s starting dose cohort . | Dose when DLT occurred . | AE recorded as DLT . | Was the AE serious? . | Severity . | Relationship to MRZ/Dex . | Action taken with MRZ /Dex . | Outcome . |
---|---|---|---|---|---|---|---|
RP2D 0.5 mg/m2 | 0.5 mg/m2 | Nausea | Yes | Grade 3 | MRZ probable/Dex not related | None | Resolved |
RP2D 0.5 mg/m2 | 0.5 mg/m2 | Confusional state | Yes | Grade 4 | MRZ probable/Dex not related | MRZ discontinued | Resolved |
0.6 mg/m2 | 0.4 mg/m2 | Gait disturbance | No | Grade 2 | MRZ probable/Dex not related | MRZ dose reduced, dose delayed | Resolved |
0.6 mg/m2 | 0.6 mg/m2 | Paranoia | No | Grade 2 | MRZ possible/Dex not related | MRZ discontinued | Resolved |